Regulus Prices IPO at $10-$12 a Share, Breaks out H1 '12 Financials | GenomeWeb

This article has been updated from a previous version to include background on previous IPOs in the RNAi/microRNA market.

Regulus Therapeutics last week disclosed that it aims to raise as much as $54 million through its planned initial public offering on the Nasdaq later this year, which would float roughly 4.5 million shares of the company at between $10 and $12 apiece.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.